The evolution of cystic fibrosis care

Chest

Volumn 148, Issue 2, 2015, Pages 533-542

  Pittman, Jessica E ^a   Ferkol, Thomas W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; ATALUREN; AZITHROMYCIN; CORTICOSTEROID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENUFOSOL; DOCOSAHEXAENOIC ACID; DORNASE ALFA; IBUPROFEN; IVACAFTOR; LUMACAFTOR; MUCOLYTIC AGENT; PLACEBO; SILDENAFIL; SODIUM CHLORIDE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CFTR PROTEIN, HUMAN; EXPECTORANT AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL LOAD; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LUNG FUNCTION TEST; MOLECULAR GENETICS; MUCOCILIARY CLEARANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPIROMETRY; THORAX RADIOGRAPHY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; GENE THERAPY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; TRENDS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EXPECTORANTS; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; PRIMARY PREVENTION;

EID: 84939224261     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-1997     Document Type: Article

References (113)

1. Farrell PM, Rosenstein BJ, White TB, et al; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153 (2): S4-S14.
2. Drumm ML, Ziady AG, Davis PB. Genetic variation and clinical heterogeneity in cystic fibrosis. A nnu Rev Pathol. 2012; 7: 267-282.
3. Quinton PM. Chloride impermeability in cystic fibrosis. N ature. 1983; 301 (5899): 421-422.
4. Knowles M, Gatzy J, Boucher R. Relative ion permeability of normal and cystic fibrosis nasal epithelium. J Clin Invest. 1983; 71 (5): 1410-1417.
5. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest. 1999; 103 (3): 309-312.
6. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet. 2008; 372 (9636): 415-417.
7. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002; 109 (5): 571-577.
8. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012; 487 (7405): 109-113.
9. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989; 245 (4922): 1059-1065.
10. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989; 245 (4922): 1073-1080.
11. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect Med. 2012; 2 (12): a009548.
12. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. M ed Clin North Am. 2000; 84 (3): 597-607.
13. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. C ell. 1993; 73 (7): 1251-1254.
14. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet. 1995; 29: 777-807.
15. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. C ell. 1990; 63 (4): 827-834.
16. Cutting GR, Kasch LM, Rosenstein BJ, et al. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990; 346 (6282): 366-369.
17. Drumm ML, Wilkinson DJ, Smit LS, et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science. 1991; 254 (5039): 1797-1799.
18. Kiesewetter S, Macek M Jr. Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background . Nat Genet. 1993; 5 (3): 274-278.
19. Stern RC, Boat TF, Doershuk CF, Tucker AS, Primiano FP Jr. Matthews LW. Course of cystic fibrosis in 95 patients. J Pediatr. 1976; 89 (3): 406-411.
20. Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators; coordinators of the Epidemiologic Study of Cystic Fibrosis. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr. 2013; 163 (4): 1152-1157.
21. Wolfenden LL, Schechter MS. Genetic and non-genetic determinants of outcomes in cystic fibrosis. P aediatr Respir Rev. 2009; 10 (1): 32-36.
22. Schechter MS. Non-genetic influences on cystic fibrosis lung disease: the role of sociodemographic characteristics, environmental exposures, and healthcare interventions. Semin Respir Crit Care Med. 2003; 24 (6): 639-652.
23. Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. P ediatr Pulmonol. 2002; 33 (6): 483-491.
24. Goss CH, Newsom SA, Schildcrout JS, Sheppard L, Kaufman JD. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med. 2004; 169 (7): 816-821.
25. Rosenfeld M, Emerson J, McNamara S, et al; EPIC Study Group Participating Clinical Sites. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol. 2010; 45 (9): 934-944.
26. Adam RJ, Michalski AS, Bauer C, et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am J Respir Crit Care Med. 2013; 188 (12): 1434-1441.
27. Hoegger MJ, Fischer AJ, McMenimen JD, et al. Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. S cience. 2014; 345 (6198): 818-822.
28. Ranganathan SC, Parsons F, Gangell C, Brennan S, Stick SM, Sly PD; Australian Respiratory Early Surveillance Team for Cystic Fibrosis. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax. 2011; 66 (5): 408-413.
29. Gaskin KJ. Nutritional care in children with cystic fibrosis: are our patients becoming better? Eur J Clin Nutr. 2013; 67 (5): 558-564.
30. Stick SM, Brennan S, Murray C, et al; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF). Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis aft er newborn screening. J Pediatr. 2009; 155 (5): 623-628.
31. Sly PD, Brennan S, Gangell C, et al; Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med. 2009; 180 (2): 146-152.
32. Linnane B, Robinson P, Ranganathan S, Stick S, Murray C. Role of high-resolution computed tomography in the detection of early cystic fibrosis lung disease. Paediatr Respir Rev. 2008; 9 (3): 168-174.
33. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. P ediatr Pulmonol. 2002; 34 (2): 91-100.
34. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. J AMA. 2005; 293 (5): 581-588.
35. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome aft er early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001; 138 (5): 699-704.
36. Sun L, Jiang RZ, Steinbach S, et al. The emergence of a highly transmissible lineage of cbl 1 Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med. 1995; 1 (7): 661-666.
37. Waters V, Atenafu EG, Salazar JG, et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros. 2012; 11 (1): 8-13.
38. Waters V, Atenafu EG, Lu A, Yau Y, Tullis E, Ratjen F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013; 12 (5): 482-486.
39. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178 (8): 814-821.
40. Esther CR Jr. Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010; 9 (2): 117-123.
41. Rabin HR, Surette MG. The cystic fibrosis airway microbiome. Curr Opin Pulm Med. 2012; 18 (6): 622-627.
42. Li L, Somerset S. The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies. Clin Nutr. 2014; 33 (4): 571-580.
43. Callaghan M, McClean S. Bacterial host interactions in cystic fibrosis. Curr Opin Microbiol. 2012; 15 (1): 71-77.
44. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168 (8): 918-951.
45. Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013; 68 (12): 1157-1162.
46. Cutting GR. Modifier genes in Mendelian disorders: the example of cystic fibrosis. A nn N Y Acad Sci. 2010; 1214: 57-69.
47. Accurso FJ, Sontag MK. Gene modifiers in cystic fibrosis. J Clin Invest. 2008; 118 (3): 839-841.
48. Drumm ML, Konstan MW, Schluchter MD, et al; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005; 353 (14): 1443-1453.
49. Sly PD, Gangell CL, Chen L, et al; AREST CF Investigators. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med. 2013; 368 (21): 1963-1970.
50. Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. C hest. 2008; 133 (2): 489-495.
51. Matthews LW, Doershuk CF, Wise M, Eddy G, Nudelman H, Spector S. A therapeutic regimen for patients with cystic fibrosis. J Pediatr. 1964; 65: 558-575.
52. Flume PA, Mogayzel PJ Jr. Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180 (9): 802-808.
53. Flume PA, Mogayzel PJ Jr. Robinson KA, Rosenblatt RL, Quittell L, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010; 182 (3): 298-306.
54. Mogayzel PJ Jr. Naureckas ET, Robinson KA, et al; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013; 187 (7): 680-689.
55. Rosenfeld M, Emerson J, Accurso F, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. P ediatr Pulmonol. 1999; 28 (5): 321-328.
56. Davis SD, Fordham LA, Brody AS, et al. Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med. 2007; 175 (9): 943-950.
57. Wainwright CE, Vidmar S, Armstrong DS, et al; ACFBAL Study Investigators. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA. 2011; 306 (2): 163-171.
58. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med. 1992; 326 (18): 1187-1191.
59. Davis SD, Brody AS, Emond MJ, Brumback LC, Rosenfeld M. Endpoints for clinical trials in young children with cystic fibrosis. Proc Am Thorac Soc. 2007; 4 (4): 418-430.
60. Mott LS, Park J, Murray CP, et al; AREST CF. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax. 2012; 67 (6): 509-516.
61. Borowitz D, Robinson KA, Rosenfeld M, et al; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009; 155 (suppl 6): S73-S93.
62. Rosenfeld M, Allen J, Arets BH, et al; American Thoracic Society Assembly on Pediatrics Working Group on Infant and Preschool Lung Function Testing. An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age. Ann Am Thorac Soc. 2013; 10 (2): S1-S11.
63. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiplebreath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax. 2008; 63 (2): 129-134.
64. Owens CM, Aurora P, Stanojevic S, et al; London Cystic Fibrosis Collaboration. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax. 2011; 66 (6): 481-488.
65. Sawyer SM, Carlin JB, DeCampo M, Bowes G. Critical evaluation of three chest radiograph scores in cystic fibrosis. Thorax. 1994; 49 (9): 863-866.
66. Puderbach M, Eichinger M, Haeselbarth J, et al. Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest X-ray. Invest Radiol. 2007; 42 (10): 715-725.
67. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001; 139 (3): 359-365.
68. Fuchs HJ, Borowitz DS, Christiansen DH, et al; The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994; 331 (10): 637-642.
69. Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations . J Pediatr. 2006; 148 (2): 259-264.
70. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function aft er cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182 (5): 627-632.
71. Sequeiros IM, Jarad NA. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis. 2012; 9 (4): 213-220.
72. VanDevanter DR, O'Riordan MA, Blumer JL, Konstan MW. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010; 11: 137-142.
73. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE. 2012; 7 (9): e45001.
74. Aaron SD, Ramotar K, Ferris W, et al. Adult cystic fibrosis exacerbations and new strains of P seudomonas aeruginosa. Am J Respir Crit Care Med. 2004; 169 (7): 811-815.
75. Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005; 4(suppl 2): 49-54.
76. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. P ediatr Pulmonol. 1997; 23 (5): 330-335.
77. Ramsey BW, Pepe MS, Quan JM, et al; Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999; 340 (1): 23-30.
78. Maíz L, Girón RM, Olveira C, et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother. 2013; 14 (9): 1135-1149.
79. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014; 11 (3): 425-434.
80. Goss CH, Ratjen F. Update in cystic fibrosis 2012. Am J Respir Crit Care Med. 2013; 187 (9): 915-919.
81. Main E, Prasad A, Schans C. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst Rev. 2005;(1): CD002011.
82. Weller PH, Bush E, Preece MA, Matthew DJ. Short-term effects of chest physiotherapy on pulmonary function in children with cystic fibrosis. R espiration. 1980; 40 (1): 53-56.
83. Quan JM, Tiddens HA, Sy JP, et al; Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr. 2001; 139 (6): 813-820.
84. Konstan MW, Wagener JS, Pasta DJ, et al; Scientific Advisory Group and Investigators and Coordinators of Epidemiologic Study of Cystic Fibrosis. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. P ediatr Pulmonol. 2011; 46 (6): 545-553.
85. Duijvestijn YC, Brand PL. Systematic review of N-acetylcysteine in cystic fibrosis. A cta Paediatr. 1999; 88 (1): 38-41.
86. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006; 354 (3): 241-250.
87. Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006; 354 (3): 229-240.
88. Rosenfeld M, Ratjen F, Brumback L, et al; ISIS Study Group. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA. 2012; 307 (21): 2269-2277.
89. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. C hest. 2008; 133 (6): 1388-1396.
90. Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. C hest. 2010; 137 (4): 861-868.
91. Deterding RR, Lavange LM, Engels JM, et al; Cystic Fibrosis Therapeutics Development Network and the Inspire 08-103 Working Group. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med. 2007; 176 (4): 362-369.
92. Ratjen F, Durham T, Navratil T, et al; TIGER-2 Study Investigator Group. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros. 2012; 11 (6): 539-549.
93. Moss RB. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis. J Pediatr. 2013; 162 (4): 676-680.
94. Althaus M. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Curr Mol Pharmacol. 2013; 6 (1): 3-12.
95. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005; 40 (6): 500-510.
96. Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. A dv Drug Deliv Rev. 2002; 54 (11): 1409-1423.
97. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. C ochrane Database Syst Rev. 2013; 6: CD001505.
98. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995; 332 (13): 848-854.
99. Cheng K, Ashby D, Smyth RL. Oral steroids for long-term use in cystic fibrosis. C ochrane Database Syst Rev. 2013; 6: CD000407.
100. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MW, Morgan WJ; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr. 2008; 153 (6): 746-751.
101. Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290 (13): 1749-1756.
102. Saiman L, Anstead M, Mayer-Hamblett N, et al; AZ0004 Azithromycin Study Group. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010; 303 (17): 1707-1715.
103. Hoffman LR, Ramsey BW. Cystic fibrosis therapeutics: the road ahead. Chest. 2013; 143 (1): 207-213.
104. Kennedy MJ. Current status of gene therapy for cystic fibrosis pulmonary disease. Am J Respir Med. 2002; 1 (5): 349-360.
105. Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat Rev Drug Discov. 2009; 8 (2): 153-171.
106. Drug development pipeline. Cystic Fibrosis Foundation website. http://www.cff.org/research/drugdevelopmentpipeline.Accessed June 19, 2014.
107. Kerem E, Konstan MW, De Boeck K, et al; Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsensemutation cystic fibrosis: a randomised, double-blind, placebocontrolled phase 3 trial. Lancet Respir Med. 2014; 2 (7): 539-547.
108. Ramsey BW, Davies J, McElvaney NG, et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18): 1663-1672.
109. KALYDECO. US Food and Drug Administration website. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/203188s008lbl.pdf. Accessed August 9, 2014.
110. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012; 67 (1): 12-18.
111. Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaft or abrogates pharmacological correction of D F508 CFTR in cystic fibrosis. S ci Transl Med. 2014; 6 (246): 246ra96.
112. Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish D F508-CFTR functional expression . Sci Transl Med. 2014; 6 (246): 246ra97.
113. Pittman JE, Cutting G, Davis SD, Ferkol T, Boucher R. Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014; 11(suppl 3): S161-S168.